Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia

Therapeutic Drug Monitoring

Volumn 36, Issue 3, 2014, Pages 378-386

  Shang, De Wei ^a,b   Li, Li Jun ^a   Wang, Xi Pei ^c   Wen, Yu Guan ^b   Ren, Yu Peng ^d   Guo, Wei ^a   Li, Wen Biao ^a   Li, Liang ^d   Zhou, Tian Yan ^d   Lu, Wei ^d   Wang, Chuan Yue ^a,e  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Clozapine; NONMEM; PK PD model; schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SIMULATION; SMOKING; TREATMENT DURATION; ADOLESCENT; BIOLOGICAL MODEL; CHINA; DOSE RESPONSE; EPIDEMIOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHINA; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; SCHIZOPHRENIA; SEX FACTORS; SMOKING; YOUNG ADULT;

EID: 84901392885     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000014     Document Type: Article

References (27)

1. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean Schizophr Res. 2005;79:231-238.
2. Golden G, Honigfeld G. Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia. Clin Drug Investig. 2008;28:231-239.
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
4. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry. 1998;59(suppl 3):38-43.
5. Bowskill SV, Patel MX, Handley SA, et al. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010. Hum Psychopharmacol. 2012;27:507-513.
6. Bowskill S, Couchman L, MacCabe JH, et al. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged 65 years and over: data from a therapeutic drug monitoring service, 1996-2010. Hum Psychopharmacol. 2012;27: 277-283.
7. Brnen S, Vincent PD, Baumann P, et al. Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit. 2011;33:561-572.
8. Li LJ, Shang DW, Li WB, et al. Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia. Acta Pharmacol Sin. 2012;33:1409-1416.
9. Ng W, Uchida H, Ismail Z, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31:360-366.
10. Zheng QM, Liao RF, Wen YG. The study on bioequivalence of clozapine orally disintegrating tablets and tablets in Chinese healthy volunteers. Guangzhou Med J. 2009;40:59-63.
11. Liu X, Huang RB, Huang JX, et al. Study on bioequivalence of clozapine orally distegrating tablets in patients with schizophrenia. Chin J Hosp Pharm. 2011;31:1936-1940.
12. Comets E, Brendel K, Mentr F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90: 154-166.
13. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1998;58:51-64.
14. Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)- A Perl module for NONMEM related programming. Comput Methods Programs Biomed. 1999;75:85-94.
15. Jerling M, Merl Y, Mentr F, et al. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol. 1997;44:447-453.
16. Lee ST, Ryu S, Nam HJ, et al. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharmacol. 2009;24:139-144.
17. Gaertner I, Gaertner HJ, Vonthein R, et al. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol. 2001;21:305-310.
18. Qiu XW, Fu PX, Wang CY, et al. Population pharmacokinetics research of clozapine in Chinese schizophrenic patients. Yao Xue Xue Bao. 2009; 44:785-792.
19. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007;46:133-157.
20. Friberg LE, de Greef R, Kerbusch T, et al. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther. 2009;86:84-91.
21. Zhao J, Li H, Peng W, et al. The influence factors on pharmacokinetics of clozapine and relationship between clinical efficacy and clozapine plasma concentration in schizophrenia. Chin Psychiatry. 1996;29:131-134.
22. Perry PJ, Bever KA, Arndt S, et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry. 1998;44:733-738.
23. Spina E, Avenoso A, Facciol G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl). 2000;148:83-89.
24. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007;27:374-379.
25. Palego L, Biondi L, Giannaccini G, et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:473-480.
26. Uchida H, Mamo DC, Pollock BG, et al. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit. 2012;34:182-187.
27. Castberg I, Westin AA, Spigset O. Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics. J Clin Psychopharmacol. 2009;29:415-420.